# Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

> **NCT00082472** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Zivena** · enrollment: 30 (—)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Doxorubicin HCl Inhalation Solution
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00082472
- **Lead sponsor:** Zivena
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2006-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082472, "Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00082472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*